http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2736822-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b4248559d5791051143afd3a5e2d124d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L15-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08J5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-7007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08J5-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-44 |
| filingDate | 2018-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a6ec6af5c63ee6ee1988239949ea0a5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57204ddf901680dada1cbe537c3d72b3 |
| publicationDate | 2020-11-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2736822-C1 |
| titleOfInvention | Structured orodispersible films |
| abstract | FIELD: medicine; pharmaceuticals.SUBSTANCE: present invention relates to a method of producing a porous orodispersible film, an orodispersible dry film. This method includes the following stages: i) preparing a suspension from a pharmaceutically acceptable solvent, a pharmaceutically acceptable matrix material and a pharmaceutically acceptable film-forming agent, wherein the solvent is selected such that the pharmaceutically acceptable matrix material is preferentially not dissolved therein, and the pharmaceutically acceptable film-forming material is dissolved therein; ii) dispensing the suspension onto a neutral substrate to form a wet film; and iii) drying the wet film to obtain a dry film. Proportion of the pharmaceutically acceptable film-forming agent in the total amount of the pharmaceutically acceptable matrix material and the film-forming agent is equal to 0.1–0.5 and the content of the solvent in terms of the total weight of the suspension in step i) is equal to 0.4–0.9. Orodispersible dry film has a dry layer thickness of 100 to 600 mcm. Theoretical film porosity is equal to 0.4–0.7. Film tensile strength is equal to 0.4–4 Nmm-2. Orodispersible dry film comprises, as components, a pharmaceutically acceptable matrix material and a pharmaceutically acceptable film-forming agent. Film has structure, according to which on one side it has solid surface, and its other side is porous.EFFECT: technical result is the development of orodispersible dry films, where one of the surfaces (on their upper side) is characterized by especially high porosity, which promotes absorption of biologically active substance applied on this side, while the opposite side of these films (their lower side) has a solid surface.19 cl, 1 tbl, 3 ex, 4 dwg |
| priorityDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.